Schrodinger Inc

Schrodinger Inc(SDGR)股票分析

$23.800

+1.264 (+5.31%)收盘时

Loading chart…
最高
23.960
开盘
22.560
成交量加权均价
23.26
成交量
1.16M
市值
1.41B
最低
22.010
成交额
26.90M
企业价值/息税折旧摊销前利润(TTM)
-8.90

Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities.

AI 分析 of Schrodinger Inc (SDGR)

持有

Schrodinger Inc (SDGR) is currently trading at $23.80, which is above the average analyst target price of $21.43, suggesting some positive sentiment. However, the RSI is at 42.886, indicating that the stock is nearing oversold territory, and the recent insider selling has increased by 609.71%, which raises concerns about potential negative sentiment. The upcoming earnings report on November 4 could significantly impact the stock's direction, making it prudent to hold off on buying until more clarity is provided.

估值指标

Schrodinger Inc(SDGR)当前预期市盈率为 0.00,5 年平均预期市盈率为 -8.79。

预期市盈率

合理
5 年均值 P/E
-8.79
当前P/E
0.00
高估
4.10
低估
-21.67

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-8.35
当前EV/EBITDA
-8.90
高估
-4.89
低估
-11.81

预期市销率

合理
5 年均值 P/S
8.22
当前P/S
6.79
高估
11.94
低估
4.50

Alphio AI 对 SDGR 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%SDGR

$27.96

情景价格

基

基准

基准 · 50%SDGR

$23.51

情景价格

悲

悲观

悲观 · 25%SDGR

$23.10

情景价格

持有 SDGR 的大户

B

Bill & Melinda Gates Foundation Asset Trust

+ 持有SDGR

+3.39%

3个月收益率

R

Rubric Capital Management LP

+ 持有SDGR

-3.70%

3个月收益率

事件时间线

2026-09-17 (ET)

12:00:00

Stocks Surge as Oil Prices Retreat

09:00:00

Schrodinger Grants 2,243 Restricted Stock Units to Three New Employees

2026-09-09 (ET)

07:30:00

Schrodinger Forms Tectora and Secures $55M Investment

2026-08-05 (ET)

17:00:00

Schrodinger Provides Financial Guidance for FY 2026

17:00:00

Schrodinger Reports Q2 Revenue of $58.889M, Beating Expectations

资讯

SDGR 常见问题 —— 由 Alphio AI 解答

Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities. It operates in the Technology sector (PHARMACEUTICAL PREPARATIONS industry).

Schrodinger Inc (SDGR) is currently trading at $23.80, which is above the average analyst target price of $21.43, suggesting some positive sentiment. However, the RSI is at 42.886, indicating that the stock is nearing oversold territory, and the recent insider selling has increased by 609.71%, which raises concerns about potential negative sentiment. The upcoming earnings report on November 4 could significantly impact the stock's direction, making it prudent to hold off on buying until more clarity is provided.

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易